Adjusting for comorbidities in cost of illness studies

Journal of Medical Economics

Volumn 18, Issue 1, 2015, Pages 12-28

  Rizzo, John A ^a   Chen, Jie ^b   Gunnarsson, Candace L ^c   Naim, Ahmad ^d   Lofland, Jennifer H ^c  

^a STONY BROOK UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c CTI Clinical Trials and Consulting S2 Statistical Solutions ^*  (United States)

^d Clinical Development   (United States)

Author keywords

Cost of illness; Diabetes mellitus; Rheumatoid arthritis

Indexed keywords

ANGINA PECTORIS; ARTICLE; ASTHMA; CEREBROVASCULAR ACCIDENT; CHRONIC BRONCHITIS; CHRONIC SINUSITIS; COLON CANCER; COMORBIDITY; CONTROLLED STUDY; COST OF ILLNESS; CYSTITIS; DEPRESSION; DIABETES MELLITUS; DIVERTICULITIS; ECZEMA; EMPHYSEMA; GASTRITIS; GASTROESOPHAGEAL REFLUX; HEALTH CARE COST; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHYROIDISM; LUNG CANCER; LUPUS VULGARIS; MIGRAINE; MULTIPLE SCLEROSIS; NEPHROLITHIASIS; OSTEOARTHRITIS; PARKINSON DISEASE; PSORIASIS; RHEUMATOID ARTHRITIS; SEBACEOUS GLAND DISEASE; SKIN CANCER; STOMACH ULCER; COMPLICATION; ECONOMICS; HEALTH CARE SURVEY; METHODOLOGY; PREVALENCE; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

ARTHRITIS, RHEUMATOID; COMORBIDITY; COST OF ILLNESS; DIABETES COMPLICATIONS; DIABETES MELLITUS; HEALTH CARE SURVEYS; HEALTH EXPENDITURES; HUMANS; MODELS, ECONOMETRIC; MODELS, STATISTICAL; PREVALENCE; RESEARCH DESIGN;

EID: 84918771125     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2014.969434     Document Type: Article

References (43)

1. Akobundu E, Ju J, Blatt L, et al. Cost-of-illness studies: a review of current methods. Pharmacoeconomics 2006;24:869-90
2. Rice DP. Cost of illness studies: what is good about them? Injury Prevention 2000;6:177-9
3. Medicare Payment Advisory Commission (MedPac). 2003. Disease management in traditional Medicare: November 4, 2003. Before the Committee on Aging U.S. Senate. Washington, DC. http://www.medpac.gov/search/searchframes. cfm. Accessed 26 September 2014
4. Graham JD, Thompson KM, Goldie SJ, et al. The cost-effectiveness of airbags by seating position. JAMA 1997;278:1418-25
5. Englander F, Hodgson TJ, Terragossa RA. Economic dimensions of slip and fall injuries. J Forens Sci 1996;41:733-46
6. Rosen A, Cutler D. Challenges in building disease-based national health accounts. Medical Care 2009;47(Suppl):S7-S13
7. Tarricone R. Cost-of-illness analysis: what room in health economics? Health Policy 2006;77:51-63
8. Shiell A, Gerard K, Donaldson C. Cost of illness studies: an aid to decision making? Health Policy 1987;8:317-23
9. Byford S, Torgerson DJ, Raftery J. Cost of illness studies. Br Med J 2000;320:1335
10. Drummond M. Cost-of-illness studies: a major headache? Pharmacoeconomics 1992;2:1-4
11. Currie G, Kerfoot KD, Donaldson C, et al. Are costs of injury studies useful? Inj Prevent 2000;6:175-6
12. Roux L, Donaldson C. Economics and obesity: costing the problem or evaluating solutions? Obes Res 2004;12:173-9
13. Corso P, Grosse S, Finkelstein E. The skinny on COI analysis. Obes Res 2004;12:1189
14. Segel JA. Cost of illness studies: a primer. Chapel Hill, NC: RTI International: RTI-UNC Center of Excellence in Health Promotion Economics, 2006
15. Honeycutt AA, Segel JE, Hoerger TJ, et al. Comparing cost-of-illness estimates from alternative approaches: An application to diabetes. Health Serv Res 2009;44:303-20
16. Lee DW, Meyer JW, Clouse J. Implications of controlling for comorbid conditions in cost-of-illness estimates: a case study of osteoarthritis from a managed care system perspective. Value Health 2001;4:329-34
17. Bloom BS, Bruno DJ, Maman DY, et al. Usefulness of US cost-of-illness studies in healthcare decision making. Pharmacoeconomics 2001;19:207-13
18. Norland A, Apelqvist J, Bitzen PO, et al. Cost of illness of adult diabetes mellitus underestimated if comorbidity not considered. J Intern Med 2001;250:57-65
19. Fleming A, Crown JM, Corbett M. Early rheumatoid disease. I. Onset. Ann Rheum Dis 1976;35:357-60
20. Scott DL, Symmons DP, Coulton BL, et al. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1987;1:1108-11
21. Pincus T, Callahan LF. What is the natural history of rheumatoid arthritis? Rheum Dis Clin North Am 1993;19:123-51
22. Ozminkowski RJ, Burton WN, Goetzel RZ, et al. The impact of rheumatoid arthritis on medical expenditures, absenteeism, and short-term disability benefits. J Occup Environ Med 2006;48:135-48
23. Michaud K, Messer J, Choi HK, et al. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum 2003;48:2750-62
24. Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 2000;39:28-33
25. Lubeck DP. A review of the direct costs of rheumatoid arthritis: managed care versus fee-for-service settings. Pharmacoeconomics 2001;19:811-18
26. Joyce AT, Smith P, Khandker R, et al. Hidden cost of rheumatoid arthritis (RA): estimating cost of comorbid cardiovascular disease and depression among patients with RA. J Rheumatol 2009;36:743-52
27. Agency for Healthcare Research and Quality (AHRQ). Medical Expenditure Panel Survey. AHRQ. 3-12-2009. Ref Type: Electronic Citation http://meps. ahrq.gov/mepsweb/. Assessed 26 September 2014
28. Cohen JW, Monheit AC, Beauregard KM, et al. The Medical Expenditure Panel Survey: a national health information resource. Inquiry 1996- 1997;33:373-89
29. Craig J. Some statistical models for limited dependent variables with application to the demand for durable goods. Econometrica 1971;39:829-44
30. Buntin M, Zaslavsky A. Too much ado about two-part models and transformation? Comparing methods of modeling Medicare expenditures. J Health Econ 2004;23:525-42
31. Mullahy J. Much ado about two: reconsidering retransformation and the twopart model in health econometrics. J Health Econ 1998;17:247-81
32. Okura Y, Urban LH, Mahoney DW, et al. Agreement between self-report questionnaires and medical record data was substantial for diabetes, hypertension, myocardial infarction and stroke but not for heart failure. J Clin Epidemiol 2004;57:1096-103
33. Alamanos Y, Drosos AA. Epidemiology of adult rheumatoid arthritis. Autoimmun Rev 2005;4:130-6
34. Spector TD. Rheumatoid arthritis. Rheum Dis Clin North Am 1990;16:513-37
35. Hahr AJ, Molitch ME. Diabetes, cardiovascular risk and nephropathy. Cardiol Clin 2010;28:467-75
36. Sprafka JM, Virnig BA, Shahar E, et al. Trends in diabetes prevalence among stroke patients and the effect of diabetes on stroke survival: the Minnesota Heart Survey. Diabetic Med 1994;11:678-84
37. Harati Y. Diabetic peripheral neuropathies. Methodist Debakey Cardiovasc J 2010;6:5-19
38. Dall T, Mann S, Zhang Y, et al. Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:596-615
39. Bolge S, Lofland J, Naim A, Rizzo J, Gunnarsson C, Chen J. PMS11 The direct medical costs of rheumatoid arthritis: evidence from United States National Survey Data. Value in Health 2010;13:A124
40. Gunnarsson C, Chen J, Rizzo JA, Ladapo JA,Lofland JH. Direct health care insurer and out-of-pocket expenditures of inflammatory bowel disease: evidence from a US national survey. Dig Dis Sci 2012:57:3080-91
41. Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Naim A, Lofland JH. The direct healthcare insurer and out-of-pocket expenditures of psoriasis: evidence from a United States national survey. J Dermatolog Treat 2012;23:240-54
42. Trogden JG, Finkelstein EA, Hoerger TJ. Use of econometric models to estimate expenditure shares. Health Serv Res 2008;43:1442-52
43. Cowie C, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination survey 1999-2002. Diabetes Care 2006;29:1263-8